Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03690362 · ClinicalTrials.gov registry record · Phase 1
VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
A Phase 1 study, sponsored by Venatorx Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03690362 is a Phase 1 study that has completed, run by Venatorx Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT03690362, a Phase 1 study, has completed, sponsored by Venatorx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, PK and safety study of VNRX-5133 and VNRX-5022 when co-administered in male and female subjects with varying levels of renal impairment and healthy normal controls.
Interventions
- DRUG VNRX-5133 and VNRX-5022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-04-06 |
| Est. Completion | 2018-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03690362
The ClinicalTrials.gov registry entry for NCT03690362 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Venatorx Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VNRX-5133 and VNRX-5022 is the first listed.
NCT03690362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03690362 about?
NCT03690362 is a clinical study titled "VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment". This is a multi-center, open-label, PK and safety study of VNRX-5133 and VNRX-5022 when co-administered in male and female subjects with varying levels of renal impairment and healthy normal controls.
What is the current status of trial NCT03690362?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2018-04-06. Estimated completion is 2018-11-21.
What interventions are being tested in trial NCT03690362?
The interventions under investigation include: VNRX-5133 and VNRX-5022 (DRUG).
Who is sponsoring clinical trial NCT03690362?
This trial is sponsored by Venatorx Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.